Stay updated with breaking news from Alison Hunt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This winter, for the first time ever, there were two vaccines available to ward off respiratory syncytial virus, which is particularly dangerous to older adults and infants. Only one of them — Abrysvo, made by Pfizer — was approved for pregnant women, and neither was for young children.
Pfizer, which dominated COVID vaccine sales, now finds itself looking up at GSK, whose rival new respiratory syncytial virus (RSV) vaccine has surged to an early lead since the shots launched this summer. The British drugmaker's early advantage may be tied to its positioning as the lone RSV shot offered by CVS Health, the biggest pharmacy chain in the U.S. and a dominant player in the retail vaccine market, analysts and industry experts say. Price may also be playing a role, according to independent pharmacists.
To prevent a repeat of last winter’s “tripledemic” of respiratory illnesses, Americans will be encouraged to roll up their sleeves
This fall, Americans will be urged to get shots against the flu, Covid and, if they’re older, R.S.V.
Americans will be encouraged to roll up their sleeves not just for flu shots but for two other vaccines, one of them entirely new.